ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "glucocorticoids"

  • Abstract Number: 2016 • ACR Convergence 2022

    Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

    Andriko Palmowski1, Sabrina Mai Nielsen2, Zhivana Boyadzhieva3, Abelina Schneider3, Anne Pankow3, Linda Hartman4, Jose Pereira da Silva5, John Kirwan6, Siegfried Wassenberg7, Christian Dejaco8, Robin Christensen9, Maarten Boers10 and Frank Buttgereit11, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, 3Charité-Universitätsmedizin Berlin, Berlin, Germany, 4Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, 5University of Coimbra, Rheumatology, Columbia, Portugal, 6University of Bristol, Bristol, United Kingdom, 7Rheumazentrum Ratingen, Ratingen, Germany, 8Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 9Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 10Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 11Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

    Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
  • Abstract Number: 0460 • ACR Convergence 2022

    Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial

    Naomi Patel1, Xiaoqing Fu2, yuqing zhang3 and John Stone4, 1Massachusetts General Hospital, Sale Creek, TN, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs). The development of future GC toxicities may be predicted by baseline toxicities. Thus,…
  • Abstract Number: 1076 • ACR Convergence 2022

    ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain

    Naomi Patel1, David Jayne2, Peter Merkel3, Pirow Bekker4, yuqing zhang5, Huibin Yue4 and John Stone6, 1Massachusetts General Hospital, Sale Creek, TN, 2University of Cambridge, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4ChemoCentryx, San Juan Capistrano, CA, 5Massachusetts General Hospital, Quincy, MA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
  • Abstract Number: 2072 • ACR Convergence 2022

    Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index

    Ilana Usiskin and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA

    Background/Purpose: Patients with lupus nephritis (LN) are often treated with high doses of glucocorticoids and experience glucocorticoid-related toxicity. Quantifying this toxicity may be a useful…
  • Abstract Number: 0461 • ACR Convergence 2022

    The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis

    Naomi Patel1, Veronica Tozzo2, John Higgins2 and John Stone3, 1Massachusetts General Hospital, Sale Creek, TN, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Hemoglobin A1c (HbA1c) is used clinically to estimate patients' average blood glucose over the preceding few months and is affected by glycemic as well…
  • Abstract Number: 1078 • ACR Convergence 2022

    Glucocorticoid Use and Related Adverse Events in ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis

    Emil De Gomma1, Peter Merkel2, Michael George3, Rennie Rhee3, Andreas Kronbichler4, David Jayne5, Huibin Yue1 and Pirow Bekker1, 1ChemoCentryx, San Juan Capistrano, CA, 2U of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4Cambridge University, Sale Creek, TN, 5University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Although the 2021 ACR/VF guidelines for ANCA-associated vasculitis (AAV) recommend reduced-dose glucocorticoids (GCs) over standard-dose GCs (1), this approach still leads to substantial toxicity,…
  • Abstract Number: 2193 • ACR Convergence 2022

    Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry

    Simon Galmiche1, Benjamin Thoreau2, Stéphane Bretagne3, Alexandre Alanio3, André Paugam4, Valérie Bru5, Sophie Cassaing6, Jean-Pierre Gangneux7, Hélène Guégan7, Loïc Favennec8, Alida Minoza9, Florent Morio10, Julie Bonhomme11, Guillaume Desoubeaux12, Odile Eloy13, Lilia Hasseine14, Milène Sasso15, Laurence Millon16, Anne-Pauline Bellanger16, Philippe Poirier17, Maxime Moniot17, Taieb Chouaki18, Antoine Huguenin19, Frédéric Dalle20, Bernard Bouteille21, Muriel Nicolas22, Nicole Desbois-Nogard23, Marie-Elisabeth Bougnoux24, François Danion25, Vincent Poindron26, Antoine Néel27, Karine Boukris-Sitbon28, Fanny Lanternier29 and Benjamin Terrier30, 1Institut Pasteur, Paris, France, 2AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, 3Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, AP-HP, Paris, France, 4Parasitologie – Mycologie, Université Paris Cité, Cochin Hospital, AP-HP, Paris, France, 5Institut de parasitologie et de pathologie tropicale, Hôpitaux universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France, 6Parasitologie - Mycologie, Université de Toulouse, CHU de Toulouse, Toulouse, France, 7Université de Rennes, CHU, INSERM, Irset: Institut de Recherche en Santé, Environnement et Travail, UMR_S 1085, Rennes, France, 8French National Cryptosporidiosis Reference Center, Rouen University Hospital, Rouen, France, 9Département des agents infectieux, Service de Mycologie-Parasitologie, CHU de Poitiers, Poitiers, France, 10Parasitologe – Mycologie, CHU de Nantes, Nantes, France, 11Microbiologie, CHU de Caen, Caen, France, 12Parasitologie - Mycologie - Médecine tropicale, CHU de Tours, Tours, France, 13Microbiologie, Hôpital de Versailles, Le Chesnay, France, 14Parasitologie – Mycologie, hôpital de l'Archet, CHU Nice, Nice, France, 15Laboratoire de Parasitologie-Mycologie, CHU Nîmes, Université de Montpellier, CNRS, IRD, MiVEGEC, Nîmes, France, 16Laboratoire de Parasitologie – Mycologie, CHU Besançon, Besançon, France, 17Parasitologie – Mycologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France, 18Mycologie – parasitologie, CHU d’Amiens, Amiens, France, 19Parasitologie – Mycologie, hôpital Maison-Blanche, CHU de Reims, Reims, France, 20Parasitologie – Mycologie, Plateforme de Biologie Hospitalo-Universitaire Gérard Mack, Dijon, France, 21Parasitologie – Mycologie, Centre de Biologie et de Recherche en Santé, CHU Dupuytren, Limoges, France, 22Mycologie – Parasitologie, CHU de Pointe-à-pitre/Abymes, Pointe-à-Pitre, France, 23Parasitologie – Mycologie, CHU de la Martinique, Fort-de-France, France, 24Institut Pasteur, Unité Biologie et Pathogénicité Fongiques, Département Mycologie, Laboratoire de Parasitologie – Mycologie, Service de Microbiologie, Necker-Enfants Malades University Hospital, AP-HP, Paris, France, 25Maladies infectieuses et tropicales, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 26Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 27CHU de Nantes, Nantes, France, 28Institut Pasteur, Université Paris Cité, CNRS, Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, Paris, France, 29Infectious Diseases Unit, Necker-Enfants Malades University Hospital, AP-HP, Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS UMR 2000, Paris, France, 30National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France

    Background/Purpose: Patients with autoimmune diseases (AIDs) display a risk of invasive fungal diseases (IFDs), because of the underlying disease or treatments used. Our objective was…
  • Abstract Number: 0481 • ACR Convergence 2022

    Glucocorticoid-related Adverse Events in Giant Cell Arteritis: Application of the Glucocorticoid Toxicity Index in a Monocentric Cohort of 140 Patients

    Francesca Regola1, Jacopo Mora1, Giovanni Bosio2, Laura Andreoli1, Franco Franceschini1 and Paola Toniati1, 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Nuclear Medicine Unit, ASST Spedali Civili of Brescia, Brescia, Italy

    Background/Purpose: Oral glucocorticoids (GC) are the mainstay of treatment for giant cell arteritis (GCA) but chronic exposure to GC is associated with serious comorbidities. The…
  • Abstract Number: 1309 • ACR Convergence 2022

    Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid

    Ji-Won Kim1, Ju-Yang Jung1, Hyoun-Ah Kim1 and Chang-Hee Suh2, 1Ajou University School of Medicine, Suwon, Republic of Korea, 2Ajou University Hospital, Suwon, Republic of Korea

    Background/Purpose: The most commonly used drugs for glucocorticoid-induced osteoporosis (GIOP) is bisphosphonates, which include oral alendronate and risedronate, and intravenous zoledronic acid. Among them, zoledronic…
  • Abstract Number: 2219 • ACR Convergence 2022

    Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

    Beth Wallace1, Yuqing Gao2, H. Myra Kim3, Punyasha Roul4, Ted Mikuls5, Daniel Clauw6, Bryant England7, Joshua Baker8, Brian Sauer9, Grant Cannon10, Shirley Cohen-Mekelberg1, Wyndy Wiitala2, Jeremy Sussman1, Rodney Hayward1 and Akbar Waljee1, 1University of Michigan Department of Internal Medicine; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, 2Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3Center for Statistical Consultation and Research, University of Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare Center, Ann Arbor, MI, 4UNMC, Omaha, NE, 5Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 6University of Michigan Department of Anesthesia, Ann Arbor, MI, 7University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA, 9Salt Lake City VA/University of Utah, Salt Lake City, UT, 10Retired, Salt Lake City, UT

    Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) at some point to manage RA symptoms. Prior work suggests recent GC use is associated with major…
  • Abstract Number: 0582 • ACR Convergence 2022

    Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases

    Xiaojuan Chai1, Yayuan Fu1, Lifeng Liu1, Yuxi Yan1, Quan Zhao1, Xiaoqing Liu2, Yixin Zou1, Jing Dai1, Feng Tang1, Zhuoxiao Cao1 and Renhong Tang1, 1Simcere Pharmaceutical Group, Shanghai, China, 2Simcere Pharmaceutical Group, Nanjing, China

    Background/Purpose: Glucocorticoids (GCs) are widely used to treat a variety of autoimmune and inflammatory diseases like rheumatoid arthritis, inflammatory bowel disease, and asthma. The anti-inflammatory…
  • Abstract Number: 1318 • ACR Convergence 2022

    Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure

    Edgar Wiebe1, Dörte Huscher2, Desirée Schaumburg1, Andriko Palmowski1, Sandra Hermann1, Thomas Buttgereit3, Robert Biesen4, Gerd Burmester5, Yannick Palmowski6, Maarten Boers7, John Stone8, Christian Dejaco9 and Frank Buttgereit10, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 3Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 4Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 5Charité University Medicine Berlin, Berlin, Germany, 6Spine Department, Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 7Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 8Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 9Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 10Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

    Background/Purpose: Inflammatory rheumatic and musculoskeletal diseases (iRMD) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GC), and…
  • Abstract Number: 0657 • ACR Convergence 2022

    DB-2304, a Novel anti-BDCA2 Monoclonal Antibody Drug Conjugate, Displayed Great Potency in Suppression of pDC Functions

    Xi Li, Yu Zhang, Bing Li and Haiqing Hua, Duality Biologics, Shanghai, China

    Background/Purpose: BDCA2 (Blood Dendritic Cell Antigen 2) is specifically expressed on plasmacytoid dendritic cells (pDCs), a type I interferon-producing cells, which have been implicated in…
  • Abstract Number: 1438 • ACR Convergence 2022

    The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry

    Isabell Nevins1, CF Allaart1, David Vega Morales2, Lai Ling Winchow3, Arvind Chopra4, Ana Maria Rodrigues5, Tom Huizinga1, Maarten Boers6 and Sytske Anne Bergstra7, 1Leiden University Medical Center, Leiden, Netherlands, 2Autonomous University of Nuevo León, Monterrey, Mexico, 3Chris hani baragwanath academic hospital, Johannesburg, South Africa, 4Center for Rheumatic Diseases, Pune, Maharashtra, India, 5Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, 6Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 7LUMC, Leiden, Netherlands

    Background/Purpose: Previous studies have demonstrated differing bDMARD prescription rates between countries, which seems to be amongst others related to a country's socioeconomic status. In contrast,…
  • Abstract Number: 0707 • ACR Convergence 2022

    Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis

    Rachel W. Galvao1, Jeffrey Curtis2, Leslie Harrold3, Qufei Wu4, Fenglong Xie5 and Michael George4, 1Yale University, New Haven, CT, 2University of Alabama at Birmingham, Hoover, AL, 3CorEvitas, LLC, Waltham, MA, 4University of Pennsylvania, Philadelphia, PA, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Glucocorticoids (GCs) are used commonly to treat patients with rheumatoid arthritis (RA) and other inflammatory conditions. As clinical trials are often underpowered to assess…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology